Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
The purpose of this study is to evaluate the rate of early and intermediate toxicity related
 to the AccuBoost System for delivery of APBI in women with resected, early stage breast
 cancer.
Inclusion Criteria:

 1. A confirmed histological diagnosis of invasive breast carcinoma or DCIS

 2. Age greater or equal to 50 years old

 3. Life expectancy > 6 months

 4. Treated by breast conserving surgery with axillary node dissection or sentinel lymph
 node biopsy

 5. Pathologic tumor size less than or equal to 2 cm

 6. Invasive ductal, mucinous, tubular or colloid histology

 7. Estrogen receptor positive for invasive carcinoma.

 8. Unifocal/unicentric disease

 9. Negative surgical margins greater than or equal to 2 mm

 10. Pathologic lymph node negative

 11. No evidence of lymphovascular invasion

 12. ECOG performance status of 0 or 1 (Appendix 1)

 13. Informed consent signed.

 Exclusion Criteria:

 1. Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)

 2. Autoimmune disorder

 3. Pregnancy

 4. Breast implants

 5. Psychiatric or addictive disorder that would preclude attending follow-up

 6. Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted)

 7. Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy
 proven benign)

 8. Lobular features on histology (pure or mixed) or sarcoma histology

 9. Node positive on axillary dissection or in the sentinel lymph node biopsy;

 10. Extensive in situ carcinoma (EIC)

 11. Multicentric or multifocal disease

 12. Paget's disease of the nipple

 13. Distant metastases

 14. Lumpectomy cavity not well visualized on AccuBoost imaging

 15. Lumpectomy cavity with 1cm margin (PTV) not adequately encompassed by any applicator
 (PTV > 6cm)

 16. Breast separation with compression > 7cm.

 17. Overlap of skin between orthogonal treatment axes.